The A4 Study: Stopping AD before Symptoms Begin?

By Reisa A. Sperling, Dorene M. Rentz, Keith A. Johnson, J. Karlawish, M. Donohue, David P. Salmon, P. Aisen. Science Translational Medicine, 2014

747 citations recorded by the source corpus.

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline. A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Subfields: Economics and Econometrics, Neurology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/217fe64e6a6afc87629db26c69b1f089cecf2666

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. Philip Scheltens
2. Lars Bertram

In Neurology

1. Kaj Blennow
2. Philip Scheltens
3. Bruno Dubois
4. William E. Klunk
5. John Hardy
6. Reisa A. Sperling
7. Clifford R. Jack Jr.
8. Keith A. Johnson

In Psychiatry and Mental health

1. Clifford R. Jack Jr.
2. Kaj Blennow
3. Reisa A. Sperling
4. John Hardy
5. Harald Hampel
6. Keith A. Johnson
7. P. Aisen
8. Philip Scheltens

Citations in the corpus

• Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, background): “The search for positive biomarkers among a large population is not feasible; hence, the trend to focus on subgroups of people where the prevalence of positive biomarkers is a priori higher [165,253].”
• Defining imaging biomarker cut points for brain aging and Alzheimer's disease (2017, neutral): “Clinical trials require a normal/abnormal classification when a biomarker is used to determine eligibility [1,2].”
• The amyloid hypothesis of Alzheimer's disease at 25 years (2016, background): “Importantly, the first prevention trial in largely pre-symptomatic humans at risk of lateonset AD (ages 65–85) based on abnormal PET amyloid scans is now underway in > 60 centers in the United States, Canada and Australia [A4study.org] (Sperling et al, 2014).”
• Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue (2015, methodology): “This compound is now quickly making its way into use in clinical research including secondary prevention trials in AD like the A4 trial.(26) Thus, a careful study to validate the sensitivity and specificity of this novel tracer and to exactly define the underlying pathological burden responsible for”
• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, neutral): “, 2017), the A4 trial enrolling participants with confirmed preclinical AD by biomarker assessment (Sperling et al., 2014), and the Alzheimer Prevention initiative (API) using a cohort of patients with ADAD as well as a separate cohort of older homozygous APOE ε4/ε4 carriers (Reiman et al.”
• Alzheimer's disease (2018, background): “The Generation study is recruiting ApoE4 individuals; and the A4 study is recruiting healthy elderly individuals with asymptomatic amyloidosis [77].”
• The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. (2018, background): “To this end, ongoing trials, such as DIAN (Dominantly Inherited Alzheimer Network trial), the Alzheimer’s Prevention Initiative, and the A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease) trial, are studying people at high risk for Alzheimer’s disease and tracking biomarkers to identify i”